|
|
 |
Business Development
In
May 2004, Lantibio out-licensed development and commercialization
of Moli901 for the treatment of cystic fibrosis in the European
Union and Eastern Europe to AOP Orphan Pharmaceuticals AG. AOP
has paid an upfront licensing fee to Lantibio and will pay future
milestone and revenue-based royalties. AOP will bear all development,
manufacturing and marketing costs in Europe. The development will
be progressed along ICH Guidelines to capitalize on the generation
of data in Europe to support regulatory submissions in North America.
Lantibio is also interested in a licensing or development partnership
for the North American development and marketing of Moli1901 for the treatment
of CF.For more information
about Moli1901 for the treatment of CF, please visit the Cystic
Fibrosis page.
Lantibio is actively pursuing licensing partners outside of North
America (primarily Europe and Japan) for Moli1901 for the treatment
of dry eye syndrome. This strategy will take advantage of international
guidelines to share development expenses across geographic markets
and capitalize on formulation and manufacturing work underway
in the United States.For more information
about Moli1901 for the treatment of dry eye syndrome, please visit
our page on Dry Eye Syndrome.In December 2005, Lantibio acquired development and commercialization rights to VISMED® through a licensing agreement and a supply manufacturing agreement with TRB Chemedica. TRB Chemedica has more than 20 years experience in the development and marketing of pharmaceutical products and is involved globally in research and development, manufacturing, registration, marketing and licensing. The therapeutic focus of TRB is rheumatology, ophthalmology and neurology and the Company has extensive experience and a particular specialization in patented products based on sodium hyaluronate, of which VISMED® is one.For more information about VISMED® for the treatment of dry eye syndrome, please visit Dry Eye Syndrome and Press Releases.
Lantibio is seeking additional ophthalmic productin-licensing candidates currently in development or on the market in Europe and/or Japan to develop and commercialize in the United States. Lantibio has isolated and sequenced the gene that encodes the Moli1901 molecule. Therefore, it is feasible to produce analogs of Moli1901 through genetic manipulation to produce a library of polypeptides providing a dynamic pipeline of drug development candidates. Lantibio will consider partnership opportunities to support its strategic goal of advancing the screening and development of appropriate analogs of Moli1901.Similarly, Lantibio is considering potential partners or licensing opportunities for two free radical scavengers, Moli56A and Moli56B. These two promising proprietary technologies remain largely unexploited, however the compounds offer potential benefit in the management of life-threatening organ failure.
To explore licensing, partnership, or collaborative opportunities,
contact us:
e-mail: partnerships@lantibio.com
FAX: 919.929.3447
|
